RT Book, Section
A1 Greene, Elisa M.
A1 Hagemann, Tracy M.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1145221578
T1 Drug-Induced Hematologic Disorders
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1145221578
RD 2024/09/17
AB KEY  CONCEPTS  The  most  common  drug-induced  hematologic  disorders  include  aplastic  anemia,  agranulocytosis,  megaloblastic  anemia,  hemolytic  anemia,  and  thrombocytopenia.  Drug-induced  hematologic  disorders  are  generally  rare  adverse  effects  associated  with  drug  therapy.  The  incidence  of  rare  adverse  drug  reactions  (ADRs)  is  usually  established  by  postmarketing  surveillance  and  reporting.  Rechallenging  a  patient  with  an  agent  suspected  of  inducing  a  blood  disorder  is  not  generally  recommended.  Drug-induced  hematologic  disorders  can  occur  by  two  mechanisms:  direct  drug  or  metabolite  toxicity  or  an  immune  reaction.  The  primary  treatment  of  drug-induced  hematologic  disorders  is  removal  of  the  drug  in  question  and  symptomatic  support  of  the  patient.